Efgartigimod alfa (Vyvgart) for Myasthenia Gravis

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2022年 / 64卷 / 1648期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：62 / 63
页数：2
相关论文
共 50 条
  • [41] Efgartigimod in generalized myasthenia gravis: A real-life experience at a national reference center
    Frangiamore, Rita
    Rinaldi, Elena
    Vanoli, Fiammetta
    Andreetta, Francesca
    Ciusani, Emilio
    Bonanno, Silvia
    Maggi, Lorenzo
    Gallone, Annamaria
    Colasuonno, Anna
    Tramacere, Irene
    Cheli, Marta
    Pinna, Alessandro
    Mantegazza, Renato
    Antozzi, Carlo
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (04)
  • [42] Case report: A highly active refractory myasthenia gravis with treatment of telitacicept combined with efgartigimod
    Zhang, Chaoyue
    Lin, Yangtao
    Kuang, Qianjin
    Li, Hongjin
    Jiang, Qilong
    Yang, Xiaojun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [43] Efgartigimod Demonstrates Consistent Improvements in Generalized Myasthenia Gravis Patients of Shorter Disease Duration
    Bril, Vera
    Vu, Tuan
    Brauer, Edward
    Kerstens, Rene
    Howard, James
    NEUROLOGY, 2023, 100 (17)
  • [44] MYASTHENIA-GRAVIS DURING INTERFERON-ALFA THERAPY
    BATOCCHI, AP
    EVOLI, A
    SERVIDEI, S
    PALMISANI, MT
    APOLLO, F
    TONALI, P
    NEUROLOGY, 1995, 45 (02) : 382 - 383
  • [45] Efgartigimod Alfa-fcab
    不详
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, : 519 - 520
  • [46] Efgartigimod Alfa-fcab
    不详
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (07) : 519 - 520
  • [47] Efgartigimod demonstrates consistent improvements in patients with generalized myasthenia gravis regardless of prior treatment failures
    Siddiqi, Zaeem
    Rozsa, Csilla
    Sacca, Francesco
    De Bleecker, Jan L.
    Verschuuren, Jan
    Hoffmann, Sarah
    Vu, Tuan
    Bril, Vera
    Murai, Hiroyuki
    Brauer, Edward
    Kerstens, Rene
    Steeland, Sophie
    Ulrichts, Peter
    Goyal, Neelam
    Vissing, John
    Mantegazza, Renato
    Howard, James F., Jr.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [48] Safety and tolerability of efgartigimod in patients with generalized myasthenia gravis: phase 3 adapt study results
    Mantegazza, R.
    Bril, V.
    Vu, T.
    Karam, C.
    Peric, S.
    Margania, T.
    Murai, H.
    Biliska, M.
    Shakarishvili, R.
    Smilowski, M.
    Guglietta, A.
    Ulrichts, P.
    Vangeneugden, T.
    Utsugisawa, K.
    Verschuuren, J.
    Howard, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 80 - 80
  • [49] Retrospective review of patients with myasthenia gravis switched from plasma exchange therapy to efgartigimod treatment
    Mehrabyan, Anahit
    Traub, Rebecca E.
    MUSCLE & NERVE, 2024, 69 (04) : 467 - 471
  • [50] Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis
    Huijbers, Maartje G.
    Plomp, Jaap J.
    van Es, Inge E.
    Fillie-Grijpma, Yvonne E.
    Kamar-Al Majidi, Samar
    Ulrichts, Peter
    de Haard, Hans
    Hofman, Erik
    van der Maarel, Silvere M.
    Verschuuren, Jan J.
    EXPERIMENTAL NEUROLOGY, 2019, 317 : 133 - 143
12345